Next Article in Journal
A Rare Cause of Pericardial Effusion and Ascites: POEMS Syndrome
Previous Article in Journal
Therapy-Related Myeloid Neoplasms as a Concerning Complication in Acute Promyelocytic Leukemia
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Dasatinib-Induced Hemorrhagic Colitis Complicated with Cytomegalovirus Infection

First Department of Internal Medicine, Kansai Medical University, Osaka 573-1191, Japan
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(4), 7415; https://doi.org/10.4081/hr.2017.7415
Submission received: 20 September 2017 / Revised: 1 October 2017 / Accepted: 9 October 2017 / Published: 22 December 2017

Abstract

A 69-year-old man with chronic-phase chronic myeloid leukemia was initially treated with 100 mg dasatinib once a day. Despite a major molecular response within 9 months, he developed hemorrhagic colitis 32 months after starting dasatinib. Colonoscopy identified multiple hemorrhagic ulcers in the transverse colon. The pathological findings indicated cytomegalovirus infection. Dasatinib was stopped and he was started on ganciclovir. Three months later, colonoscopy confirmed the disappearance of the hemorrhagic ulcers. Dasatinib is a second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia. As a multi-kinase inhibitor that acts on SRC-family kinases, its broader off-target kinase-inhibitory activity may account for the adverse events of dasatinib. Although gastrointestinal bleeding is common in patients taking dasatinib, the combination of cytomegalovirus infection and hemorrhagic colitis in the absence of systemic immunodeficiency is rare. Based on this case of dasatinibinduced hemorrhagic colitis with cytomegalovirus infection, we describe a possible mechanism and effective treatment.
Keywords: dasatinib; hemorrhagic colitis; cytomegalovirus; chronic myeloid leukemia dasatinib; hemorrhagic colitis; cytomegalovirus; chronic myeloid leukemia

Share and Cite

MDPI and ACS Style

Nakaya, A.; Azuma, Y.; Fujita, S.; Satake, A.; Nakanishi, T.; Tsubokura, Y.; Konishi, A.; Hotta, M.; Yoshimura, H.; Ishii, K.; et al. Dasatinib-Induced Hemorrhagic Colitis Complicated with Cytomegalovirus Infection. Hematol. Rep. 2017, 9, 7415. https://doi.org/10.4081/hr.2017.7415

AMA Style

Nakaya A, Azuma Y, Fujita S, Satake A, Nakanishi T, Tsubokura Y, Konishi A, Hotta M, Yoshimura H, Ishii K, et al. Dasatinib-Induced Hemorrhagic Colitis Complicated with Cytomegalovirus Infection. Hematology Reports. 2017; 9(4):7415. https://doi.org/10.4081/hr.2017.7415

Chicago/Turabian Style

Nakaya, Aya, Yoshiko Azuma, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yukie Tsubokura, Akiko Konishi, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, and et al. 2017. "Dasatinib-Induced Hemorrhagic Colitis Complicated with Cytomegalovirus Infection" Hematology Reports 9, no. 4: 7415. https://doi.org/10.4081/hr.2017.7415

APA Style

Nakaya, A., Azuma, Y., Fujita, S., Satake, A., Nakanishi, T., Tsubokura, Y., Konishi, A., Hotta, M., Yoshimura, H., Ishii, K., Ito, T., & Nomura, S. (2017). Dasatinib-Induced Hemorrhagic Colitis Complicated with Cytomegalovirus Infection. Hematology Reports, 9(4), 7415. https://doi.org/10.4081/hr.2017.7415

Article Metrics

Back to TopTop